Dataset Information

Co-immunoprecipitation and proteomic analysis of Major Histocompatibility Complex Class I-related (MR1) mutants

ABSTRACT: Identification of cellular proteins mediating presentation of bacterial antigens by the MHC I-related protein MR1. MR1 mutant proteins that differ in their capacity to present antigens from different sources were immunoprecipitated and their interacting proteins were compared to identify candidate proteins involved in the different antigen presentation pathways.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

SUBMITTER: Jason Krawic

LAB HEAD: William Hildebrand

PROVIDER: PXD063725 | Pride | 2026-04-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	22-1102-MR1_CHAP_42_TD-MUT-129-D4.wiff	Wiff
	22-1102-MR1_CHAP_42_TD-MUT-129-D4.wiff.scan	Wiff
	22-1102-MR1_CHAP_42_TD-MUT-129-D6.wiff	Wiff
	22-1102-MR1_CHAP_42_TD-MUT-129-D6.wiff.scan	Wiff
	22-1102-MR1_CHAP_42_TD-MUT-131-D4.wiff	Wiff

Items per page:

1 - 5 of 14

Publications

Mutations outside the MR1 antigen binding groove differentially inhibit presentation of exogenous antigens.

Kulicke Corinna A CA Lemon Chance C Krawic Jason R JR Nieto Ramirez Luisa Maria LM Kim Se-Jin SJ Narayanan Gitanjali G Tafesse Fikadu G FG Hildebrand William H WH Dobos Karen M KM Lewinsohn David M DM

The Journal of biological chemistry 20260226 4

The antigen presenting molecule major histocompatibility complex class I-related protein 1 (MR1) binds small molecule metabolites derived from the microbial riboflavin biosynthetic pathway and presents them at the cell surface for surveillance by MR1-restricted mucosal-associated invariant T cells (MAIT cells). MR1 ligands can originate in the extracellular space or in endosomal compartments that contain microbial pathogens. Distinct, complementary antigen processing and presentation pathways en ...[more]

PMID: 41759736

Similar Datasets

Project description:Immune evasion is an important hallmark of cancer ensured by diverse strategies, including immunosuppression and downregulation of antigen presentation. Here, to restore immunogenicity of cancer cells, we employed the minimal gene regulatory network of highly immunogenic type 1 conventional dendritic cells (cDC1) to reprogram cancer cells into professional antigen presenting cells (APCs). We showed that enforced expression of PU.1, IRF8 and BATF3 (PIB) was sufficient to induce cDC1 phenotype in 33 cell lines derived from human and mouse hematological and solid tumors. PIB gradually modified the cancer cell transcriptional and epigenetic program imposing global antigen presentation and cDC1 gene signatures within 9 days. cDC1 reprogramming restored the expression of antigen presentation complexes as well as co-stimulatory molecules at the cell surface, leading to the presentation of endogenous antigens on MHC-I, and to CD8+ T cell mediated killing. Functionally, tumor- APCs acquired the ability to uptake and process exogenous proteins and dead cells, secreted inflammatory cytokines and cross-presented antigens to naïve CD8+ T cells. Importantly, tumor-APCs were efficiently generated at the single cell level from primary cancer cells of 7 solid tumors that presented antigens to memory and naïve T-cells, as well as to activated patient-specific intra-tumoral lymphocytes. Alongside antigen presentation, tumor-APCs harboring TP53, KRAS and PTEN mutations showed impaired tumorigenicity in vitro and in vivo. Finally, using in vivo mouse models of melanoma, we showed that intra-tumoral injection of tumor-APCs promoted lymphoid infiltration, delayed tumor growth and increased survival. The anti-tumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors enabling tumor eradication. Our approach combines cDC1’s antigen processing and presenting abilities with endogenous generation of tumor antigens and serves as a platform for the development of novel immunotherapies based on endowed antigen presentation in cancer cells.